 NEW YORK, April 5, 2021 PRNewswire -- AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, AIkidos primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. 